Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Armata Pharmaceuticals (NYSE American: ARMP), a biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant infections, has announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Armata Pharmaceuticals (NYSE American: ARMP), a biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant infections, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is set to take place in New York from September 9-11, 2024.
Dr. Deborah Birx, Armata's Chief Executive Officer, will deliver a corporate presentation on Wednesday, September 11, from 8:00-8:30 AM ET. This presentation offers an opportunity for investors to gain insights into Armata's innovative approach to treating difficult-to-treat bacterial infections using high-purity, pathogen-specific bacteriophage therapeutics.
Details
News Market Reaction – ARMP
The recorded move for ARMP in the trading session of this news was -3.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Armata's presentation is scheduled for Wednesday, September 11, from 8:00-8:30 AM ET.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Media Contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-26th-annual-global-investment-conference-302238686.html
SOURCE Armata Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.